Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/92979
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKar, P.en
dc.contributor.authorJones, K.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorDeane, A.en
dc.date.issued2015en
dc.identifier.citationWorld Journal of Diabetes, 2015; 6(5):693-706en
dc.identifier.issn1948-9358en
dc.identifier.issn1948-9358en
dc.identifier.urihttp://hdl.handle.net/2440/92979-
dc.description.abstractCritical illness in patients with pre-existing diabetes frequently causes deterioration in glycaemic control. Despite the prevalence of diabetes in patients admitted to hospital and intensive care units, the ideal management of hyperglycaemia in these groups is uncertain. There are data that suggest that acute hyperglycaemia in critically ill patients without diabetes is associated with increased mortality and morbidity. Exogenous insulin to keep blood glucose concentrations < 10 mmol/L is accepted as standard of care in this group. However, preliminary data have recently been reported that suggest that chronic hyperglycaemia may result in conditioning, which protects these patients against damage mediated by acute hyperglycaemia. Furthermore, acute glucose-lowering to < 10 mmol/L in patients with diabetes with inadequate glycaemic control prior to their critical illness appears to have the capacity to cause harm. This review focuses on glycaemic control in critically ill patients with type 2 diabetes, the potential for harm from glucose-lowering and the rationale for personalised therapy.en
dc.description.statementofresponsibilityPalash Kar, Karen L Jones, Michael Horowitz and Adam M Deaneen
dc.language.isoenen
dc.publisherBaishideng Publishingen
dc.rights© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/en
dc.subjectDiabetes; critically ill; intensive care; management; personalised therapyen
dc.titleManagement of critically ill patients with type 2 diabetes: the need for personalised therapyen
dc.typeJournal articleen
dc.identifier.rmid0030030689en
dc.identifier.doi10.4239/wjd.v6.i5.693en
dc.identifier.pubid190243-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS12en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidDeane, A. [0000-0002-7620-5577]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_92979.pdfPublished version860.38 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.